The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Nagendran Sukumar since 2017.
This trader's CIK number is 1665124.
At the time of last reporting, Nagendran Sukumar was the President and Head of R&D of Taysha Gene Therapies, Inc.. (stock ticker symbol TSHA).
Also see all insider trading activities at Taysha Gene Therapies, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | AVXS | 0 | $0 | 5,340 | $631,651 | 5,340 | $98,628 |
| 2017 | AVXS | 0 | $0 | 16,021 | $1,408,906 | 16,021 | $295,903 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | TSHA | 0 | $0 | 57,054 | $162,603 | 0 | $0 |
| 2023 | TSHA | 5,000 | $3,400 | 0 | $0 | 0 | $0 |
| 2022 | TSHA | 10,000 | $80,100 | 0 | $0 | 0 | $0 |
2. Taysha Gene Therapies, Inc. (TSHA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-03-01 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2018-03-01 | AVXS | Sale | 1,780 | 125.50 | 223,397 |
| 2018-02-01 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2018-02-01 | AVXS | Sale | 1,780 | 119.54 | 212,784 |
| 2018-01-02 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2018-01-02 | AVXS | Sale | 1,780 | 109.81 | 195,470 |
| 2017-12-01 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2017-12-01 | AVXS | Sale | 1,780 | 94.82 | 168,774 |
| 2017-11-01 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2017-11-01 | AVXS | Sale | 1,780 | 102.37 | 182,220 |
| 2017-10-02 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2017-10-02 | AVXS | Sale | 1,780 | 97.77 | 174,021 |
| 2017-09-01 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2017-09-01 | AVXS | Sale | 1,780 | 93.42 | 166,287 |
| 2017-08-01 | AVXS | Sale | 1,780 | 91.97 | 163,706 |
| 2017-08-01 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2017-07-03 | AVXS | Sale | 1,780 | 82.04 | 146,031 |
| 2017-07-03 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2017-06-01 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2017-06-01 | AVXS | Sale | 1,780 | 71.10 | 126,557 |
| 2017-05-01 | AVXS | Option Ex | 1,780 | 18.47 | 32,876 |
| 2017-05-01 | AVXS | Sale | 1,780 | 81.87 | 145,723 |
| 2017-04-03 | AVXS | Sale | 1,781 | 76.13 | 135,587 |
| 2017-04-03 | AVXS | Option Ex | 1,781 | 18.47 | 32,895 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-21 | TSHA | Sale | 57,054 | 2.85 | 162,603 |
| 2023-05-16 | TSHA | Buy | 5,000 | .68 | 3,400 |
| 2022-02-02 | TSHA | Buy | 10,000 | 8.01 | 80,100 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Nagendran Sukumar (President and Head of R&D of Taysha Gene Therapies, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.